Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Serina Therapeutics, Inc. (SER : AMEX)

• Company Description    Serina Therapeutics Inc. is a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases. Serina Therapeutics Inc., formerly known as AgeX Therapeutics Inc., is based in HUNTSVILLE, Ala. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $1.98 Daily Weekly Monthly 20 Day Moving Average: 74,535 shares Shares Outstanding: 15.00 (millions) Market Capitalization: $29.70 (millions) Beta: 1.15 52 Week High: $7.92 52 Week Low: $1.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.06% -2.92% 12 Week 9.39% 1.13% Year To Date 3.50% -9.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 601 GENOME WAY SUITE 2001 - HUNTSVILLE,AL 35806 USA ph: 256-327-9630 fax: 510-671-8619 None https://serinatherapeutics.com

• General Corporate Information    Officers Steve Ledger - Chief Executive Officer and Director Balkrishan (Simba) Gill - Executive Chairman of the Board of Director Gregory S. Curhan - Chief Financial Officer Gregory H. Bailey - Director Stephen Brannan - Director Peer Information Serina Therapeutics, Inc. (CORR.) Serina Therapeutics, Inc. (RSPI) Serina Therapeutics, Inc. (CGXP) Serina Therapeutics, Inc. (BGEN) Serina Therapeutics, Inc. (GTBP) Serina Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81751A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 15.00 Most Recent Split Date: 3.00 (0.03:1) Beta: 1.15 Market Capitalization: $29.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -18.37% vs. Previous Quarter: -87.10% Sales Growth vs. Year Ago Period: 154.90% vs. Previous Quarter: -% ROE 03/31/26 - -8,051.54 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -155.08 12/31/25 - -221.90 09/30/25 - -213.58 Current Ratio 03/31/26 - 4.18 12/31/25 - 1.71 09/30/25 - 1.31 Quick Ratio 03/31/26 - 4.18 12/31/25 - 1.71 09/30/25 - 1.31 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -16,358.46 12/31/25 - -14,766.92 09/30/25 - -16,061.21 Book Value 03/31/26 - 0.85 12/31/25 - -0.46 09/30/25 - -0.32 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.24 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - 14.59 12/31/25 - - 09/30/25 - 0.00

Powered by Zacks Investment Research ©